MW
Roles
Ligand Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Promacta/Revolade (eltrombopag) | Chronic ITP, Aplastic Anemia | Marketed |
| Kyprolis (carfilzomib) | Multiple Myeloma | Marketed |
| Veklury (remdesivir) | COVID-19 | Marketed |
| Vascepa (icosapent ethyl) | Cardiovascular Risk Reduction | Marketed |
| Jemperli (dostarlimab) | Endometrial Cancer | Marketed |
| VK2735 (Viking Partnership) | NASH, Obesity | Phase 2 |
| Ibrexafungerp (Scynexis Partnership) | Fungal Infections | Marketed |
Leadership Team at Ligand Pharmaceuticals
JL
John L. Higgins
Chief Executive Officer
CS
Charles S. Berkman
Senior Vice President, General Counsel and Secretary
TC
Todd C. Davis
Senior Vice President, Corporate Development
JR
Jennifer R. Cochran
Chair of the Board of Directors